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INTRODUCTION
Myasthenia gravis (MG) is one of the most common autoimmune neurological diseases and affects the neuromuscular junction. [1] Although there are many therapeutic methods such as immunosuppressive therapy and steroids which are generally regarded as the effective preventive measures leading to marked symptomatic improvement in the majority of MG patients, there are many cases who still experience fluctuating muscle weakness and fatigability to some degree, or develop myasthenic crisis even after a clinical remission. [2] [3] [4] [5] Yet the factors predicting the symptomatic fluctuation have not been well defined.
MG is mainly mediated by acetylcholine receptor antibodies (AChR-Ab), which were demonstrated to be associated with the severity of disease in individuals. [6] However, the heterogeneity of AChR-Ab and no elevated titers of AChR-ab in the minority of MG patients limited the clinical significance of measuring the antibodies. [1, 7] In addition, there are some patients with elevated titers of antibodies against musclespecific kinase (MuSK), Titin, RyR and LRP4, [8] [9] [10] [11] signifying the heterogeneity of the autoimmune disease. Identification of specific markers of disease activity and severity is of great interest to clinicians. Changes in peripheral lymphocyte subsets were reported in patients with MG as well as patients with other autoimmune diseases, including systemic lupus erythematosus, [12] rheumatoid arthritis [13] and Sjogren's syndrome, [14, 15] suggesting that these abnormal distributions of lymphocyte subsets may be involved in the pathogenesis of autoimmune diseases. [16] [17] [18] [19] CD4 + T helper cells have an important role in an experimental animal model of myasthenia gravis (EAMG) and MG patients as they influence autoreactive B cell production of anti-AChR antibodies. [20] Th1, Th2, Th17 and regulatory T (Treg) cells, which were differentiated from Naïve CD4 + T cells, have been shown to be involved in the pathogenesis of MG. [21] B cells, because of the key contribution to humoral immune responses involving the secretion of antibodies, are generally considered to be pathogenic in the majority of autoimmune diseases. Recent evidence indicates that specific B cell subsets can negatively regulate immune responses by constraining Th1 and Th17 responses, indicative of the existence of regulatory B (Breg) cells. [22] Natural killer (NK) cells predominantly participate in the innate immune response to infections. NK cell-derived interferon-gamma activates Th1 helper cells, [23] and NK cells can impact acquired immunity. The subsets of lymphocytes mentioned above have been demonstrated to be involved in the pathogenesis of MG, but the role of lymphocyte subsets in symptomatic exacerbation in MG patients is not fully understood.
NK cells which play an important role during viral infection and tumor diseases, were considered to be involved in the regulation of autoimmunity in animal models and in humans. [24] [25] [26] NK cell numbers were found to decline with progression of most autoimmune diseases of humans. [27] [28] [29] Interestingly, the number of NK cells was increased significantly after plasmapheresis in patients with MG, indicating that they may become an important marker for monitoring clinical activation in MG patients. [16] Traditionally, B cells have been thought to contribute to the antigen (Ag)-specific autoantibody production. Nonetheless, the role of B cells extends beyond the production of antibodies in autoimmune diseases. Recently, B cell subsets with regulatory functions were identified and the studies focused on Breg cells, also known as B10 cells, which express IL-10 and CD1d
+ phenotypes. [30] [31] [32] Recent studies showed that Breg cells can prevent the development of EAMG, [33] and were involved in patients with autoimmune diseases. [31, [34] [35] [36] However, whether there are corresponding changes in Breg cells associated with severity of diseases remains elusive.
In this study, we investigated the changes in peripheral NK cells and Bregs in MG patients experiencing deterioration, in attempt to find a reliable marker for MG activity and for monitoring effectiveness of immunotherapy.
METHODS

Patients
In this study, 54 patients with MG who met the standard clinical criteria [37] 
Flow cytometric analysis
The peripheral blood samples from all the participants were obtained by venipuncture and stored in tubes containing ethylene diamine tetraacetic acid (5.4 mg/tube). Each sample was divided into 2 tubes, each one containing 100 µL fresh whole blood which was further incubated with 5 µL of mAbs (Becton Dickinson) for 20 min in dark at room temperature. Breg cells were stained with FITC conjugated antihuman CD19, PE conjugated anti-human CD1d, APC conjugated anti-human CD5, and NK cells were analyzed after staining with PE conjugated anti-human CD16, PerCP conjugated anti-human CD3, APC conjugated anti-human CD56, respectively. Isotype- 
Statistical analysis
All statistical analyses were performed using the SPSS software application. The data were expressed as the mean ± standard error. For a comparison of the different subgroups of the MG patients and the healthy controls, the data were analyzed using twotailed Student's t-test. P-values lower than 0.05 were considered to be statistically significant. ± 3.81 ). Yet the increase was less than that in GMG patients in remission stage and there was no statistical difference. The percentage of NK cells in the GMG patients at exacerbation stage also tended to increase, but the difference was not significant when compared with that in the healthy controls (12.32 ± 1.42). In order to determine whether NK cell frequencies were associated with symptomatic exacerbation, the percentages of NK cells were compared between the two subgroups of GMG patients. The frequency of NK cells in the patients in remission were significantly increased compared to patients in exacerbation (20.69 ± 3.45 vs. 12.32 ± 1.42, P = 0.017, Table 4 , Figure 2 ). The data suggest that NK cells are involved in the pathogenesis of MG and mayplay a protective role during development of the disease.
Frequency of lymphocyte subsets in patients with exacerbation and infection
It's well known that various factors such as infections, inappropriate drug use, or neuro-endocrine dysfunction will lead to of muscle weakness in MG patients. Among the predisposing factors, infections were the most frequently identified for symptomatic exacerbation in our study [ Table 5 ]. So, we have further analyzed peripheral blood lymphocyte subsets in the patients with infections at the exacerbation stage. Our data showed that the patients with infections had significantly lower percentage of NK cells those without infections during exacerbation (10.97 ± 1.74;
14.03 ± 2.36, Table 5 , Figure 3) , suggesting that the NK cells may be consumed by infections or by a similar mechanism during deterioration of muscle weakness. Furthermore, the difference in NK cells percentages between the patients in exacerbation with infections and the cases in remission was significant (P = 0.028), but the difference between the patients in exacerbation without infections and the cases in remission was not statistically significant [ Table 5 ; Figure 3 ]. The 
DISCUSSION
Disorders of neuromuscular junction can be of immunological, toxic, or genetic origin; and among these rare disorders, MG is the most common. The clinical hallmark of MG is a fluctuating weakness and fatigability of the affected voluntary muscles. With the advent of immunotherapy, the long-term outcome has been improved significantly, [39] but the symptomatic deterioration after symptomatic remission takes places in majority of MG patients including both the OMG and GMG cases. [40] [41] [42] Thus, reliable markers that reflect the activity of the disease to guide the clinical therapy are critical.
MG patients present with heterogeneous clinical patterns in terms of onset-age, initial symptoms, mode of development, thymic abnormalities, immunological profiles, and responsiveness to treatment. MG is currently considered to consist of a heterogeneous group of autoimmune diseases, which share common aspects, such as the impairment of neuromuscular transmission induced by autoimmunity, manifested by muscle weakness and fatigability and the response to both pyridostigmine and immunosuppressants. [43] In MG, the presence of multiple autoantibodies against numerous targeted molecules (e.g. AChR-ab). These antibodies suggest altered immunity, but any single antibody determination is hardly reflective of the progression or activity of the disease. The production of the above-mentioned antibodies are likely the result of the dysfunctioned lymphocytes, thus measuring the peripheral lymphocytes subsets in MG patients may be a promising way to monitor the progression of the disease.
B cell abnormalities contribute to the development and progress of autoimmune diseases. Traditionally, the predominant function of B cells was thought to be limited to production of autoantibodies. However, B cells have both positive and negative regulatory roles during immune responses. During murine development the absence of B cells results in significant quantitative and qualitative abnormalities within the immune system, including a remarkable decrease in thymocytes numbers, [44] defects within spleen dendritic cells and T cells compartments. [45, 46] Through production of immunomodulatory cytokines, B cells can also negatively regulate cellular immune responses. A variety of regulatory B cell subsets have been described. Whether Breg cells can serve as a marker for disease activity in MG remains to be determined. Our observation showed that the percentage of Breg cells was significantly decreased in the peripheral blood of GMG patients, indicating that Breg cells are affected during the development of the disease. But when we further focused on the changes of Breg cells between the two subgroups of GMG, no significant difference was found between them. This interesting finding suggests that the peripheral Breg cells dysfunction may contribute to the development of MG, but are likely not a main factor in the acute exacerbation of disease. Thus, more detailed studies on the subsets of Breg cells may provide valuable insights into the role of Breg cells in MG.
NK cells are large granular cells that constitute 5-10% of circulating lymphocytes in humans, and are important effectors in innate immunity. [29] Increasing studies report that NK cells can also act as regulators in adaptive immunity by producing cytokines which modulate the downstream immune factors. [47] [48] [49] In addition, NK cells were found to play a protective role in several autoimmune disease models. [50] [51] [52] In EAMG, Liu et al. [53] reported that NK cells proliferate in the early stages of the disease; the percentage of NK cells then decrease with disease progression. Based on the observations, NK cells were suggested to activate CD4 + T lymphocytes. A previous report showed that the activity of NK cells in the blood of MG patients was lower than that of the controls. [54] Further, Suzuki et al. [55] showed that the frequencies of NK cell infections; yet, the mechanism for the increase in NK cells is unknown. These findings are consistent with Suzuki et al., [55] which suggested that NK cells in the blood of patients at exacerbation stage may transfer to the neuromuscular junction, where immune cells obviously accumulate. At the stage of remission, NK cells might then transfer back to peripheral blood. It will be very interesting to compare the NK cell density in the neuromuscular junction among the patients in different stages. However, how the NK cells migrate at different stages and how NK cells are involved in the pathogenesis of MG remains to be fully elucidated. Based on our initial study, we also suggest that developing approaches that restore and boost the activity of NK cells may improve the MG symptoms and have therapeutic value.
Studies on the immune mechanism of OMG are scarce. However, in our study, both the Breg cells and NK cells were not obviously changed in the OMG patients. Actually, childhood onset MG (CMG), predominantly manifested isolated ocular symptoms, shows many different aspects from the adult onset MG, such as the rare transformation from the ocular type to generalized types, the scarcity of thymomas, and the lacking benefit of thymectomy in CMG. [41] We are convinced that the CMG with ocular type represents a different clinical entity in which the immunologic pathogenesis is far from being understood.
In conclusion, lymphocyte subsets were obviously disordered in GMG patients. The decrease of the peripheral Breg cells is linked with development of GMG, while the increase of peripheral NK cells is associated with reduced MG symptoms. Our research reveals that the frequency of the NK cells could be a reliable marker for MG activity in GMG patients. Restoring and boosting the activity of NK cells could be of therapeutic value. Therefore, a prospective, randomized clinical trial is required to further delineate the significance of NK cells in MG patients.
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